American Tech Today
SEE OTHER BRANDS

Hottest science and technology news from the United States

American Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.

Press releases published on May 29, 2025

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate …

Reflect Scientific Completes $550,000 Next-Generation Freezer Installation for Pharmaceutical Client

Reflect Scientific Completes $550,000 Next-Generation Freezer Installation for Pharmaceutical Client

OREM, Utah, May 29, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leader in ultra-low temperature freezer technology, today announced the successful completion of a major installation project valued at $550,000. The deployment, which …

Septerna to Present at Jefferies Global Healthcare Conference

Septerna to Present at Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive …

Trident Resources Announces Appointment of Scott Broughton as Strategic Advisor

Trident Resources Announces Appointment of Scott Broughton as Strategic Advisor

Vancouver, BC, May 29, 2025 (GLOBE NEWSWIRE) -- Trident Resources Corp. (TSX-V: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company”) is pleased to announce the appointment of Mr. Scott Broughton as a Strategic Advisor. Scott Broughton is an accomplished mine …

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that …

Maxus Mining Announces Listing on the Frankfurt Stock Exchange Under the Symbol R7V

Maxus Mining Announces Listing on the Frankfurt Stock Exchange Under the Symbol R7V

VANCOUVER, British Columbia, May 29, 2025 (GLOBE NEWSWIRE) -- Maxus Mining Inc. (“Maxus” or the “Company”) (CSE: MAXM | FRA: R7V), is pleased to announce that its common shares are now trading on the Frankfurt Stock Exchange (“FSE”) under the symbol “R7V”, …

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its presentation at the …

Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders

Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders

DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced …

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the …

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune …

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will …

Erasca to Present at Upcoming Investor Conferences in June

Erasca to Present at Upcoming Investor Conferences in June

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today …

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that …

Bridge 2 Technologies (B2T) to Host Landmark 5th Anniversary Global Intellect Summit, Uniting Business Leaders for Transformative Growth

Bridge 2 Technologies (B2T) to Host Landmark 5th Anniversary Global Intellect Summit, Uniting Business Leaders for Transformative Growth

DANVILLE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Bridge 2 Technologies (B2T), the breakthrough technology company reshaping global commerce through its innovative business ecosystem and cutting-edge technology platform, announces its milestone fifth …

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient …

UK regulated cloud mining: Earn Mining launches new short-term contracts and free mining opportunities

UK regulated cloud mining: Earn Mining launches new short-term contracts and free mining opportunities

Brisbane, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- As the best cloud mining platform in 2025, it does not require the purchase of expensive mining machines. Users can mine online without any equipment and obtain stable income. Cloud mining is becoming …

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment …

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders

- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for …

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service